The expression of TP53 mutation of GNG5, MAL2, SLC25A15, PTDSS1 in patients with BLCA were significantly increased compared to non-mutation group, and all predicted target genes were markedly increased compared to normal group (Figure 11). This evidence concerns the gene TP53 and bladder transitional cell carcinoma.